Clinical data from Cyclarity Therapeutics demonstrates safe urinary excretion of 7-ketocholesterol, a toxic oxidized cholesterol form embedded in arterial plaque, marking the first human evidence of removing accumulated cardiovascular damage rather than merely slowing its progression. This shift from risk reduction to damage removal represents a substantive change in how cardiovascular disease might be addressed at the mechanistic level.
Key Points
- UDP-003 therapy safely removes 7KC from arterial plaque via urine
- First human evidence of active damage removal, not just progression slowing
- Cyclodextrin mechanism physically captures oxidized cholesterol for excretion
Longevity Analysis
The ability to clear accumulated oxidized cholesterol from vessel walls addresses a fundamental problem in aging: the progressive accumulation of biological damage that downstream interventions cannot reverse. Arterial integrity underpins function across multiple systems—from oxygen delivery and metabolic efficiency to cognitive resilience and renal function. Rather than managing cholesterol production or inflammatory markers, this approach directly removes the corrosive byproducts already embedded in tissues, which aligns with an emerging understanding that longevity gains may require addressing root-level damage accumulation alongside prevention of new damage formation.
Original published by Longevity.Technology, by Kyle Umipig.